2024
Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study
Ryckman T, McQuaid C, Cohen T, Menzies N, Kendall E. Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study. The Lancet Global Health 2024, 12: e1629-e1637. PMID: 39159654, PMCID: PMC11413512, DOI: 10.1016/s2214-109x(24)00284-5.Peer-Reviewed Original ResearchStandard of careInitial treatment attemptNewly diagnosed tuberculosis patientsTuberculosis burdenTreatment attemptDrug susceptibility testingProportion of patientsMechanisms of benefitNon-drug costsRifampicin susceptibilityTreatment discontinuationIncremental curingSusceptibility testingDrug susceptibilityRegimen developmentTreatment regimenTuberculosis patientsRegimenRegimensTuberculosis treatmentInjection regimensTuberculosis diagnosisRegimen assignmentsNon-adherenceSimulated cohortPotential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC
McQuaid C, Ryckman T, Menzies N, White R, Cohen T, Kendall E. Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 1571-1579. PMID: 39043388, PMCID: PMC11286077, DOI: 10.3201/eid3008.240541.Peer-Reviewed Original ResearchConceptsResistance to novel drugsStandard of careAntimicrobial resistanceIncreasing prevalence of antimicrobial resistancePrevalence of antimicrobial resistanceIncreased prevalenceDrug susceptibility testingCompare treatment outcomesFirst-line drugsNovel drugsTB patient cohortTreatment regimensPatient cohortNew tuberculosisRegimensTreatment outcomesComponent drugsDrugCohortTuberculosisCDCUniversal useClinicCarePrevalence
2017
A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis
Fofana MO, Shrestha S, Knight GM, Cohen T, White RG, Cobelens F, Dowdy DW. A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis. Antimicrobial Agents And Chemotherapy 2017, 61: 10.1128/aac.00498-16. PMID: 27956422, PMCID: PMC5328532, DOI: 10.1128/aac.00498-16.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsBayes TheoremBiological AvailabilityComputer SimulationDrug Administration ScheduleDrug Resistance, Multiple, BacterialExtensively Drug-Resistant TuberculosisFluoroquinolonesHumansMicrobial Sensitivity TestsModels, StatisticalMycobacterium tuberculosisPyrazinamideRifampinTuberculosis, PulmonaryConceptsCompanion drugsExtensively Drug-Resistant TuberculosisSecond-line treatmentFirst-line treatmentSecond-line regimensDrug-resistant tuberculosisUse of pyrazinamideExtensive drug resistanceDrug resistance dataEmergence of strainsEmergence of mutationsXDR-TBSequential regimensHIV infectionAlternative drugsResistance amplificationPyrazinamide resistanceProlonged treatmentCombination antimicrobialsDrug resistanceInfectious diseasesPrevalenceProportion of simulationsAppropriate useRegimens
2016
Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective
Kendall EA, Cohen T, Mitnick CD, Dowdy DW. Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. International Journal Of Infectious Diseases 2016, 56: 185-189. PMID: 28007660, PMCID: PMC5576040, DOI: 10.1016/j.ijid.2016.12.010.Peer-Reviewed Original ResearchConceptsSecond-line drug susceptibility testingRifampin-resistant tuberculosisDrug susceptibility testingSecond-line drug resistanceDrug resistanceSusceptibility testingHigh-burden settingsSecond-line drugsDrug-resistant tuberculosisEffective regimensTreatment failureTreatment outcomesSmall incremental costEpidemiologic benefitsResistance amplificationPatientsTuberculosisIncremental costMost settingsWidespread implementationSettingRegimensPrevalence
2014
Drivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis
Shrestha S, Knight GM, Fofana M, Cohen T, White RG, Cobelens F, Dowdy DW. Drivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis. Open Forum Infectious Diseases 2014, 1: ofu073. PMID: 25734143, PMCID: PMC4281792, DOI: 10.1093/ofid/ofu073.Peer-Reviewed Original ResearchDrug-resistant TBTreatment of tuberculosisNew drug regimenTransmission fitnessDrug regimensDrug regimenTreatment successDrug-susceptible TBAppropriate second-line therapyDR-TB prevalenceSecond-line therapyDrug resistance trendsTreatment success rateHigher treatment successNovel drug regimensEmergence of resistancePopulation-level dataTB regimensShort-term surveillanceDS-TBNew regimenClinical trialsEarly diagnosisRegimensDrug resistance
2013
Isoniazid-resistant Tuberculosis in Children
Yuen CM, Tolman AW, Cohen T, Parr JB, Keshavjee S, Becerra MC. Isoniazid-resistant Tuberculosis in Children. The Pediatric Infectious Disease Journal 2013, 32: e217-e226. PMID: 23348808, PMCID: PMC3709006, DOI: 10.1097/inf.0b013e3182865409.Peer-Reviewed Original ResearchConceptsIsoniazid-resistant tuberculosisLatent tuberculosis infectionTuberculosis diseaseTuberculosis infectionIsoniazid resistancePediatric tuberculosis patientsTreatment of childrenIsoniazid-resistant strainsReports of childrenEffective regimensTuberculosis patientsTuberculosis treatmentAppropriate treatmentInclusion criteriaMedian proportionSystematic reviewRifampin resistanceDiseaseTuberculosisRegimensChildrenTreatmentInfectionIsoniazidHigher proportion
2011
Multiple Introductions of Multidrug-Resistant Tuberculosis into Households, Lima, Peru - Volume 17, Number 6—June 2011 - Emerging Infectious Diseases journal - CDC
Cohen T, Murray M, Abubakar I, Zhang Z, Sloutsky A, Arteaga F, Chalco K, Franke MF, Becerra MC. Multiple Introductions of Multidrug-Resistant Tuberculosis into Households, Lima, Peru - Volume 17, Number 6—June 2011 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2011, 17: 969-975. PMID: 21749756, PMCID: PMC3358204, DOI: 10.3201/eid1706.101471.Peer-Reviewed Original ResearchConceptsMDR-TB patientsMDR-TBMultidrug-resistant tuberculosisTB patientsOptimal treatment regimensMDR Mycobacterium tuberculosisDrug sensitivity testingHigh incidence areaRepetitive unit-variable number tandem repeatHousehold contactsTreatment regimensHousehold transmissionSecondary casesPatientsMycobacterium tuberculosisSensitivity testingCommunity exposureTuberculosisNumber tandem repeatTBSecond strainExposureRegimensSpoligotyping